Epithelial–mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. Issue 48 (29th November 2018)

• Record Type: Journal Article
• Authors: van Staalduinen, Jente; Baker, David; ten Dijke, Peter; van Dam, Hans
• Is Part Of: Oncogene. Volume 37:Issue 48(2018)
• Page Start: 6195
• Page End: 6211
• Publication Date: 2018-11-29
• Subjects: Oncogenes -- Periodicals; Oncogenes; Oncogenes -- Periodicals; Electronic journals; Periodicals; 616.994042
• DOI: 10.1038/s41388-018-0378-x
• Languages: English
• ISSNs: 0950-9232

Abstract

Abstract Chemoresistance remains a major complication of cancer treatments. Recent data provide strong evidence that chemoresistance is linked to epithelial–mesenchymal transition (EMT), a latent developmental process, which is re-activated during cancer progression. EMT involves transcriptional reprogramming and is driven by specific EMT transcription factors (EMT-TFs). In this review, we provide support for the idea that EMT-TFs contribute to the development of resistance against cancer therapy and discuss how EMT-TFs might be targeted to advance novel therapeutic approaches to the treatment of cancer.